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Abstract
Background: During clinical trials in emergency medicine, providing appropriate oral and written information
to a patient is usually a challenge. There is little published information regarding patients' opinions and
competence to provide informed consent, nor on physicians' attitudes towards the process. We have investigated
the problem of obtaining consent from patients in emergency-setting clinical trials (such as acute coronary
syndromes (ACS) and stroke) from a physicians' perspective.
Methods: A standardised anonymous 14-item questionnaire was distributed to Polish cardiac and stroke centres.
Results: Two hundred and fourteen informative investigator responses were received. Of these investigators,
73.8% had experience with ACS and 25.2% had experience with acute stroke trials (and 1% with both fields). The
complete model of informed consent (embracing all aspects required by Good Clinical Practice (GCP) and law)
was used in 53.3% of cases in emergency settings, whereas the legal option of proxy consent was not used at all.
While less than 15% of respondents considered written information to have been fully read by patients, 80.4%
thought that the amount of information being given to emergency patients is too lengthy. Although there is no
legal obligation, more than half of the investigators sought parallel consent (assent) from patients' relatives. Most
investigators confirmed that they would adopt the model proposed by the GCP guidelines: abbreviated verbal and
written consent in emergency conditions with obligatory "all-embracing" deferred consent to continue the trial
once the patient is able to provide it. However, this model would not follow current Polish and European
legislation.
Conclusion: An update of national and European regulations is required to enable implementation of the
emergency trial consent model referred to in GCP guidelines.
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Despite tremendous advances in pharmacotherapy over
recent decades, the expectations of both medical profes-
sionals and patients towards more effective and safer ther-
apies are even greater. This is particularly true for
treatment of vascular diseases such as acute coronary syn-
dromes (ACS) and acute stroke, considering the numer-
ous complications that can occur. Although treatments of
ACS and stroke have improved greatly with thrombolytic
and percutaneous coronary interventions, both condi-
tions still have major therapeutic needs. To satisfy these
needs, much research is being conducted by both
academia and industry. However, in the era of the evi-
dence-based medicine, novel therapies, even in emer-
gency settings, must be accompanied by essential
documentation of their pre-clinical and clinical efficacy
and safety to be approved for general use. Clinical
research nowadays is governed by widely accepted strict
ethical and quality standards, based on the Declaration of
Helsinki [1] and Good Clinical Practice (GCP) guidelines
(Good Clinical Practice standards by the International
Conference on Harmonisation, ICH, 1996, also intro-
duced into general law in most European countries over
recent years by the means of two European Community
directives, 2001/20/EC and 2005/28/EC). Essential to
these standards are the respect of autonomy of research
participants and the importance of their well-being over
the interests of science and society. Therefore one of the
most fundamental principles of modern clinical research
is the informed consent of participants. In the case of
emergency trials, however, giving appropriate oral and
written information to a prospective participant is usually
a challenge for researchers and treating physicians. The
informed consent process has to compete with the cate-
gorical need of starting necessary diagnostic procedures as
quickly as possible, short therapeutic windows, and fre-
quently impaired or absent patient's competence to give
informed consent due to poor physical or mental state,
shock, neurological deficit, or even unconsciousness
[2,3]. Evidence exists that participation in acute coronary
trials may delay the start of the reperfusion therapy[4],
and at least a part of that delay might be due to a patients'
involvement in the informed consent process. It has been
recently demonstrated that allowing deferred consent for
enrolment in a traumatic brain injury (TBI) trial reduces
time to study drug administration by 50% compared to
written proxy consent [5].
In the European countries, the ethical and legal environ-
ment for conducting biomedical research involving
humans has dramatically changed over the last decade.
This is due to the inflow of industry-sponsored GCP-com-
pliant clinical trials, adoption of modern medical and
pharma laws, the update of national and international
ethical codes and conventions, and the implementation
of relevant European Union directives. From the perspec-
tive of a Polish national, there are a number of conflicting
statements in the national medical and pharma laws
which have built up a nebulous environment for emer-
gency research investigators. Specifically, these include a
waiver from participant's consent, no regulations for a
deferred consent, and restrictive regulations for proxy
(surrogate) consent, as well as a remarkable tradition of
involving patient's relatives in information and/or con-
sent process.
Little is known about either a patients' competence to give
consent, or their general opinion on emergency research
[6,7]. A recent report, written following interview of a
group of 12 American stroke patients, demonstrates
patients' willingness to participate in emergency research,
as well as acceptance of a waiver of consent [8]. Notewor-
thy evidence also exists that the public is aware of the
importance of emergency research and that the normal
rules for consent may not be easily applicable in these cir-
cumstances [9]. Likewise, little is known on physicians'
attitudes, especially in terms of informed consent of
research participants. Only anecdotal reports are availa-
ble, such as that by Ågard et al. who investigated the atti-
tudes of Swedish cardiologists to ACS research in 2004
[10], or a survey among European neuro-trauma centres
on TBI trials in 2005 [11]. This has led us to investigate the
problem of informed consent in emergency settings from
the perspective of Polish physicians' who have frequently
faced such issues in practice when conducting ACS or
stroke trials.
Methods
A standardised anonymous 14-item questionnaire (for
detailed content see Table 1) was sent out in 2006 to all
identified in-patient Polish cardiac and stroke centres (43
and 22, respectively). Ten copies were sent per centre. The
questionnaires were accompanied by supporting letters
from the heads of national reference centres for heart dis-
eases and stroke (co-authors of this paper, A.B. and A.C.,
respectively). Stamped addressed envelopes were pro-
vided for easy response. Additionally, approximately 300
copies of the questionnaire were given for countrywide
distribution and collection by clinical trial monitors, in
person. The monitors were employed by 6 pharmaceutical
company sponsors and contract research organisations
who confirmed that they had conducted trials with ACS or
recent stroke in Poland, and who agreed to voluntarily
contribute to our research (see Acknowledgements).
Again, stamped addressed envelopes were provided for
easy response. Thirty-seven copies of the questionnaire
were e-mailed to investigators conducting a large multi-
centre ACS trial (sponsored by Eli Lilly), and approxi-
mately 30 copies were personally distributed and
completed at investigators' meetings organised by thePage 2 of 6
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Trials 2008, 9:45 http://www.trialsjournal.com/content/9/1/45Table 1: Questionnaire items (in order of appearance) and respective percentage of answers obtained




What was the scope of the trial information and 
how was it delivered to trial participants?**
all-embracing information, verbal + 
written***
53.3% 47.5% 70.4%
abbreviated information, verbal and 
written
38.8% 41.8% 29.6%
all-embracing verbal + abbreviated 
written information***
15.0% 14.6% 13.0%
abbreviated verbal + all-embracing 
written information***
10.7% 12.0% 7.4%
abbreviated verbal information only 4.2% 4.4% 3.7%
proxy consent (by guardianship court) only 0.0% 0.0% 0.0%
Did you additionally seek consent of participants' 
relative(s), if available?
yes, always 18.3% 9.5% 44.4%
yes, sometimes 43.7% 41.4% 48.1%
rarely or exceptionally 25.3% 32.5% 5.6%
never 12.7% 16.6% 1.9%
Following enrolment, did you inform 
participants' relative(s), if available, about their 
trial participation?
yes, always 54.2% 43.0% 87.0%
yes, sometimes 33.7% 41.8% 11.1%
rarely or exceptionally 9.8% 12.7% 1.9%
never 2.3% 2.5% 0.0%
Did the involvement of a participant's relative(s) 
influence the time necessary to obtain informed 
consent?
yes, delayed 55.6% 55.1% 57.4%
yes, shortened 6.6% 6.3% 7.4%
no influence 29.4% 27.8% 35.2%
not applicable (no involvement) 8.4% 10.8% 0.0%
How do patients react to a trial proposal in an 
emergency condition?
positively/somewhat positively 65.7% 61.1% 77.8%
equal proportions for positive and negative 
responses
29.1% 33.8% 16.7%
negatively/somewhat negatively 1.0% 1.3% 0.0%
uncertain 4.2% 3.8% 5.5%
Is an emergency (conscious) patient able to 
understand the nature of the trial and 
consciously decide whether or not to 
participate?
always/most often 32.3% 31.7% 33.3%
some patients are able 46.7% 43.0% 59.3%
no or few patients are able 17.3% 20.9% 5.6%
uncertain 3.7% 4.4% 1.8%
How much of the verbal information received by 
the patient is really understood?
all/almost all 32.9% 33.8% 31.5%
some 58.2% 58.6% 55.5%
almost none 1.9% 2.5% 0.0%
uncertain 7.0% 5.1% 13.0%Page 3 of 6
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1000 copies of the questionnaire were distributed. In each
case, clear instructions were provided to ensure that the
questionnaire was only completed by physicians who had
been personally involved in obtaining consent for admin-
istering a drug in an emergency clinical trial setting.
Results
Two-hundred and eighteen completed questionnaires
were returned (213 paper and 5 electronic copies). We
considered this amount to be representative for the target
group of physicians, taking into account the number of
cardiologists and neurologists in Poland (approx. 1400
and 2000, respectively, plus presumably several hundreds
of young physicians with ongoing specialisation or resi-
dency in those fields). We also considered the fact that
only a proportion of them work in inpatient cardiac and
stroke centres (no detailed national data on how many;
presumably approx. 1/4 of each population), of which
only a proportion have conducted emergency clinical tri-
als. Informative responses were 97.2 – 100.0% per ques-
tion. Four questionnaires were excluded from further
How much of the written trial information 
does an emergency patient actually read?
all/almost all 14.5% 13.3% 18.5%
some 62.1% 62.0% 61.1%
almost none 19.2% 21.5% 13.0%
uncertain 4.2% 3.2% 7.4%
The amount of information supposed to be 
given to patient was, in general:
too comprehensive 80.4% 85.4% 64.8%
adequate in regard to the patient's condition 17.7% 13.3% 31.5%
too brief 0.0% 0.0% 0.0%
uncertain 1.9% 1.3% 3.7%
How does a trial proposal to an emergency 
patient affect their trust in the physician?
increases trust 26.3% 27.4% 24.1%
neither increases nor decreases trust 48.3% 49.0% 46.3%
decreases trust 9.9% 10.2% 9.2%
uncertain 15.5% 13.4% 20.4%
Does informing a participant's relative(s) 
about their trial participation make sense at all?
yes 68.1% 63.3% 83.0%
no 12.7% 14.6% 5.7%
uncertain 19.2% 22.1% 11.3%
Which of the following models of informed 
consent in emergency settings would be the 
best?
all-embracing information (like non-
emergency trials), verbal and written***
14.0% 11.4% 22.2%
abbreviated information, verbal and 
written + abbreviated consent form, with 
obligatory all-embracing written consent to 
continue the trial once the participant's status 
has sufficiently improved (ICH GCP-
based)***
78.0% 81.7% 66.7%
abbreviated oral information + only verbal 
consent, with obligatory all-embracing 
written consent to continue the trial once 
the participant's status has sufficiently 
improved (currently unrealistic under 
national regulations)***
7.5% 6.3% 11.1%
other model 0.5% 0.6% 0.0%
* two respondents declaring experience with both acute coronary syndrome and stroke trials were not taken into account for subgroup analysis
** multiple choice possible; all other items were single choice
*** embracing all aspects required by Good Clinical Practice (GCP) and law for a regular trial
Table 1: Questionnaire items (in order of appearance) and respective percentage of answers obtained (Continued)Page 4 of 6
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reported (other emergency conditions only). One hun-
dred and fifty eight responders (73.8%) declared experi-
ence with obtaining informed consent in ACS trials (of
these 67.7% were trials sponsored by industry, 1.3% were
academic, 27.8% were involved in both academia and
industry-sponsored trials, and 3.2% gave no answer).
Fifty-four responders (25.2%) had experience with acute
stroke (of these 61.1% were in trials sponsored by indus-
try, 13.0% were academic, 24.1% were involved in both
academia and industry-sponsored trials, and 1.8% gave
no answer). Two responders (1.0%) had experience with
both ACS and acute stroke trials: one through clinical tri-
als sponsored by industry and one through both industry
and academia. In addition, 26 responders from both
groups have also reported experience with informed con-
sent processes in other emergency therapeutic fields
(arrhythmia, acute heart failure, injury, epilepsy and
migraine).
Each component of the questionnaire, and the corre-
sponding percentage of informative answers obtained, is
presented in Table 1.
Discussion and conclusion
Our results show a lack of consistency in current practice
for delivering trial-related information to ACS and stroke
patients. The most commonly delivered consent model is
based on complete written and verbal information ("all-
embracing" in terms of the 20 items defined in ICH GCP,
possibly extended by national ethical and legal stand-
ards). This consent methodology is even more frequent in
acute stroke than ACS trials. Even though a legal option
based on proxy consent (by guardianship court in case of
Poland) exists for performing trials in acutely incompe-
tent patients, it was not used by any of our respondents.
In our opinion, this finding demonstrates the inadequacy
of involvement of external bodies for proxy consent in
emergency settings, at least with the current model of their
functioning in practice.
Investigators' perceptions of patients' reactions to emer-
gency trials were predominantly positive (more pro-
nounced in acute stroke subgroup). Investigators
generally did not feel that they had compromised their
patients trust. However, most patients were regarded to be
only partially able to understand the nature of the trial.
While more than 90% of investigators think verbal com-
munication is entirely or partially understood by emer-
gency patients, less than 15% of respondents consider that
written information is fully read by patients, and as many
as 19.2% (even more in the ACS subgroup) observe that
almost none of the written information is read. This cor-
responds with results available from literature on the lim-
ited competence of acute coronary patients, as well as
stroke patients, to give informed consent [12-15]. In par-
ticular, the low rate of patients having read the informa-
tion sheet, as perceived by our respondents, correlates
well with the percentage of patients who admitted to hav-
ing not read the information sheet (25%) in a recent ACS
trial DANAMI-2 [16]. The vast majority of investigators
(especially ACS trialists) consider the amount of informa-
tion given to emergency patients to be too lengthy. This
finding supports the pioneer research by Mader and Playe
in late 1990's who concluded that informed consent
forms used in emergency medicine research may be too
complex for the average patient to understand [17]. These
findings do however need verification by studies directly
looking at emergency patients' perception and their actual
understanding of trial information. Such research is
sparse, in particular in the European setting [18].
Although no formal requirement exists (neither legal nor
stated in the national Medical Code of Ethics), more than
50% of investigators (and almost all acute stroke trialists)
sought, more or less frequently, parallel consent (assent)
of patients' relatives (if available), even if it increased the
time necessary to obtain consent. This supports the study
by Kane et al. who found that obtaining assent from a
patient's relative was the most frequently chosen option
by investigators of a recent international stroke trial [19].
This also corresponds with the results of the study by
Kompanje et al. among neuro-trauma physicians, 48% of
whom considered patients relatives, in turn, as unable to
make a balanced decision towards treatment [11]. Fur-
thermore, nearly 90% of investigators in our survey (and
almost all acute stroke trialists) informed relatives of trial
participants of their actual participation. Our data show
that involvement of emergency patients' relatives in the
consent process, at least in the form of delivering informa-
tion on trial participation, should be considered when
updating ethical codes and legal regulations.
The last point on the questionnaire tried to establish
which was the preferrential model for obtaining informed
consent in emergency settings. The response to this ques-
tion was strikingly repetitive. As many as 78% of investi-
gators (even more in the ACS subgroup) favoured the two-
step model proposed by the ICH GCP guidelines: abbre-
viated verbal and written consent in emergency condi-
tions along with obligatory "all-embracing" deferred
consent to continue the trial once the participants' status
has sufficiently improved. This is in line with other evi-
dence collected, where psychological and sociological
methods demonstrate that a simplified informed consent
procedure in an emergency setting may result in better
understanding and retention of information by partici-
pants [18]. Together with our results, this supports the
concept of simplified consent under emergency condi-
tions and makes the deferral of complete consent ethicallyPage 5 of 6
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information by participants constitutes the principal
aspect of informed consenting. However, this model con-
flicts with the current European legislation (requiring
either "all-embracing" verbal and written information in
order to obtain the patient's own consent or, alternatively,
absolute proxy consent), as regulated by the Directive
2001/20/EC and implemented respectively to national
laws, including Polish. This inadequacy of European leg-
islation towards emergency research has already been
highlighted by other authors [20,21], in contrast to the
modern US regulations on emergency research allowing a
waiver from consent [22]. We believe that our data sup-
ports the need to update the European regulations by
building on the model of emergency trial consent found
in ICH GCP guidelines.
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